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Abstract
Background: Hürthle cell carcinoma is a variant of follicular cell carcinoma of thyroid. It may
present as a low-grade tumour or as a more aggressive type. Prognosis depends upon the age of
the patient, tumour size, extent of invasion and initial nodal or distant metastasis.
Patient and methods: The case of Hürthle cell carcinoma is reported in a 79-year-old man who
presented with a rapidly increasing lump on the left side of his neck, having had a right
hemithyroidectomy for colloid goitre 24-years-ago. Fine needle aspiration cytology confirmed the
presence of Hürthle cells, raising the possibility of a Hürthle cell neoplasm. The patient underwent
staging and surgery. Histology showed Hürthle cell carcinoma and the patient underwent adjuvant
therapy. The literature on Hürthle cell neoplasms is reviewed.
Conclusions: Fine needle aspiration cytology may recognise Hürthle cell lesion but final diagnosis
of carcinoma depends upon histological confirmation of vascular or capsular invasion. Staging and
surgery in Hürthle cell carcinoma are similar to follicular carcinoma of thyroid with favourable
outcome despite the controversy regarding the histological classification and adjuvant therapy.
Elderly patients with Hürthle cell carcinoma need to be made aware of their poorer prognosis and
should be offered more radical treatment.
Background
The natural history of Hürthle cell carcinoma (HCC) is
not well understood. It accounts for <5% of all differenti-
ated thyroid malignancies. Hürthle cells are characterised
by eosinophilic cytoplasm with trabecular/follicular
growth pattern. [1]. Oncocytes are seen in follicular cell
carcinoma but in HCC oncocytes represent more than
75% of cells, which exhibit a rather more trabecular
growth pattern [2]. There is much debate regarding its
clinical behaviour and little is known about the long-term
survival of patients with HCC. Some studies have reported
a relatively benign course while others have found the
tumour to behave aggressively [3-6]. Most studies show
that advanced age (>45), male sex, size of primary tumour
(>4 cm), degree of invasion and recurrence are poor prog-
nostic indicators [6-8]. Fine needle aspiration cytology is
a good predictor of Hürthle cell neoplasm but is of little
diagnostic value in evaluating HCC, since for a tumour to
be deemed malignant one has to show vascular or capsu-
lar invasion [9]. Intraoperative frozen sections have a low
predictive value. Udelsman et al found that in 96.4% cases
with follicular neoplasm of thyroid, frozen section was
neither informative nor cost-effective [10]. Well-encapsu-
lated HCC run a favourable course while locally advanced
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HCC are associated with higher mortality and should be
treated aggressively [4,11]. In a well-differentiated thyroid
carcinoma death resulting from local disease is unusual
and most die of distant metastases [12].
We report a case of a Hürthle cell carcinoma presenting in
the left lobe of thyroid following a right hemithyroidec-
tomy for a colloid goitre 24 years ago.
Case presentation
A 79-year-old male was referred in March 2003 with a
lump on the left side of his neck. The patient had noted a
sudden increase in the size of the lump over the preceding
two months. He did not report any neck pressure symp-
toms, weight loss or anorexia. His past history included
right partial thyroidectomy for a solitary nodule (colloid
goitre) in 1978 and repair of abdominal aortic aneurysm
in 1994. He had suffered myocardial infarction in 1995
and had an episode of acute coronary insufficiency in Jan-
uary 2003. His recent coronary angiograms showed an
occluded left anterior descending artery and echocardio-
gram revealed good left ventricular function. He was a
non-smoker and consumed alcohol in moderation. He
had been taking warfarin, diltiazem MR, lisinopril, uni-
phyllin, glyceryl trinitrate tablets and buccal suscard.
On examination he had left sided goitre extending superi-
orly into the posterior triangle and inferiorly into the ret-
rosternal space, with variable consistency. The trachea was
deviated to the right and there was cervical lymphadenop-
athy on the left side. Systemic examination was unremark-
able and fine needle aspiration of thyroid gland showed
presence of Hürthle cells. Computerised tomographic
(CT) scan with contrast enhancement (figure 1 &2) of the
neck and thorax revealed large left sided thyroid goitre
with significant mediastinal extension. It showed mixed
attenuation with foci of calcification peripherally. There
was a 3 cm complex mass on the left side of the neck, pos-
terior to the carotid sheath structures and deep to the ster-
nomastoid, indicative of lymph node metastases. Thyroid
profile and routine blood investigations were
unremarkable.
Based on the above findings radical surgery was planned.
On exploration of the neck we confirmed left goitre with
intrathoracic extension and enlarged lymph nodes under
the sternocleidomastoid close to the jugulodigastric mus-
cle and surrounding the carotid sheath. There was no rem-
nant thyroid tissue seen on the right side following the
previous thyroid surgery. Left hemithyroidectomy with
modified neck dissection (lymphadenectomy, preserving
all vessels and nerves) was performed. Macroscopic exam-
ination of the thyroid lobe showed a well defined solid
pale brown mass approximately 8 cm in maximum
dimension, surrounded by a narrow rim of preserved thy-
roid tissue. The lymph node specimen comprised of sev-
eral nodules of partly necrotic tissue. Microscopic
examination showed the thyroid lobe containing a
Hürthle cell neoplasm, which was mostly encapsulated,
with foci of capsular and vascular invasion. The two
lymph nodes revealed metastatic Hürthle cell carcinoma.
[pT3, N1a, Mx], (Figure 3 &4).
The patient had adjuvant therapy with oral radioiodine
131 (3060 MBq Sodium Iodine). He was put on a daily
dose of 100 mcg of thyroxine. This was to be followed by
a second dose of 5911 MBq of radioactive iodine six
months from the time of the first dose.
Discussion
Hürthle cell carcinomas are heterogeneous neoplasms
that display a wide range of biological behaviour and
accounts for less than 5% of all differentiated thyroid
malignancies. The term HCC should be restricted to
tumours with more than 75% of oncocytic cells [2]. Onco-
cytes are seen in follicular thyroid cell carcinoma and in
papillary thyroid cell carcinoma [13,14]. On one hand
patients with HCC live for years with slow growing
tumour and lymphatic metastases and on the other hand,
patients die of highly aggressive tumour with haematoge-
nous spread.
Our patient had several indicators for poor prognosis such
as his advanced age, male gender, large tumour size (8
cm), extra thyroid extension and nodal metastasis. Inter-
estingly enough the patient had no pressure symptoms
despite marked deviation of larynx, trachea and oesopha-
gus, which may be due to previous right hemithyroidec-
tomy. In elderly patients with sudden enlargement of neck
mass and pre-existing thyroid conditions such as benign
thyroid nodule, goitre (as in our case), Grave's disease or
differentiated thyroid carcinoma, one has to bear in mind
anaplastic thyroid carcinoma (ATC). In ATC local com-
pression symptoms such as hoarseness, strider, dyspnoea
and dysphagia occur as a rule [15-17]. In aggressive type
of HCC haematogenous spread has been noted, but in
ATC, at presentation patients are quite likely to have dis-
tant metastases involving lung, bone, brain and soft tis-
sues [15,16].
Our patient had undergone fine needle aspiration cytol-
ogy, which revealed Hürthle cells. Since the lesion was
rapidly growing with mediastinal extension and nodal
involvement, the patient underwent staging and left
hemithyroidectomy with modified neck dissection. His-
tology confirmed HCC based on vascular and capsular
invasion. Intraoperative frozen sections have low predic-
tive value and are particularly not a sensitive test for diag-
nosing HCC therefore this was not carried out [10].World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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McIvor et al have clearly shown that FNAC can easily
recognise the tumour as Hürthle cell lesion [9]. Cases with
suspicious histology and over 50 years of age carry a high
risk of cancer [18].
In the management of HCC the primary mode of treat-
ment is surgical, ranging from hemithyroidectomy to total
thyroidectomy. Larger tumours (>T2) require total thy-
roidectomy and lymphadenectomy if lymph nodes are
involved [8]. Adjuvant radioiodine treatment or external
beam radiotherapy is used for widely invasive carcinoma
or locally advanced disease [8].
Several reports in literature have identified contra lateral
foci of carcinoma in 40–70% of cases of HCC [11,19].
HCC is less responsive to radioactive iodine therapy [20]
and taking into account the aggressive behaviour, it has
been suggested that every Hürthle cell tumour greater
than 2 cm should be treated by total thyroidectomy [21].
In 1990 they showed that recurrent disease was noted in
17% of patients treated with total thyroidectomy com-
pared to 59% in cases where a more limited procedure
was carried out [21,22]. Other authors support the role of
total thyroidectomy as there is 15 to 35% incidence of
multiple foci in HCC [23].
There are several reasons favouring the use of 131I remnant
ablation after near-total thyroidectomy [24]. First, pres-
ence of thyroid remnant can obscure 131I uptake in cervi-
cal or lung metastases [25,26]. Second, distant (lung)
metastases may be seen only on the post treatment whole
body scan after remnant ablation [27]. Finally, remnant
Superior extension of left goitre with 3 cm diameter complex mass deep to sternomastoid, posterior to carotid sheath Figure 1
Superior extension of left goitre with 3 cm diameter complex mass deep to sternomastoid, posterior to carotid sheath. Note 
the displacement of larynx to the right.World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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ablation may destroy residual normal follicular cells,
which may become malignant [28] and any occult cancer
that may recur years later.
Radioiodine therapy has no overall effect on mortality but
subgroup analysis has shown that those patients who
receive radioactive iodine for adjuvant ablation of rem-
nant thyroid tissue have lower mortality rate compared
with patients who either did not receive treatment or in
whom the indication was the presence of residual disease
[29]. Radioiodine uptake in the elderly is much lower.
Schlumberger and colleagues noted 131I uptake at meta-
Mediastinal extension of left goitre Figure 2
Mediastinal extension of left goitre.World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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static sites in only 53% of patients over 40 years of age,
compared to 90% in patients below the age of 40 [30].
Univariate analysis indicated that older age and large
tumour size predicted worse survival rates due to aggres-
sive nature of the tumour (extra glandular invasion and
multifocal disease). One recent series reviewed medical
records of patients between the years 1944 and 1995. Of
the 89 HCC cases studied, 29% had only undergone
lobectomy as initial treatment and 50% had undergone
partial resection. Of the three quarters of the patients in
this series who received radioactive iodine, only 38% of
patients with known metastases showed positive uptake
[29]. Another study clearly suggested that treatment with
131I to ablate the thyroid remnant and to treat residual dis-
ease were independent prognostic variables that favoura-
bly influenced recurrence, distant recurrence, and cancer
death rates [24]. Our patient received radioactive iodine
treatment in the postoperative period. He has been fol-
lowed up with whole body scans (Fig 5 and 6), which
indicate his response to adjuvant radioactive iodine
therapy. He is on 125 mcg thyroxine in order to maintain
a TSH level of less than 0.01 mIU/L and FT4 at the upper
limit of normal (8–28 pmol/L).
Stojdinovic  et al have treated 56 patients with HCC
between the years 1940 and 2000 [8]. Of these patients
23(41%) had minimally invasive disease with no evi-
dence of extra thyroid invasion (T2 N0 M0) and 33(56%)
had widely invasive HCC. Primary mode of treatment was
surgery ranging from lobectomy and isthumusectomy to
total thyroidectomy with cervical lymphadenectomy in
presence of lymph node involvement. Some patients
received adjuvant radioiodine or external beam radiother-
apy for widely invasive carcinoma. Study end points were
Photomicrograph showing capsular invasion (Haematoxylin and Eosin ×200) Figure 3
Photomicrograph showing capsular invasion (Haematoxylin and Eosin ×200)World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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relapse free survival and disease specific survival. They
reported 8 years survival rate of 100% and 58% for low
and high-risk cancers respectively. In their entire study
cohort age was not found to predict the outcome but the
most significant factor was widely invasive carcinoma.
Khafif et al in their series (42 patients with HCC between
1957–1997) used radioiodine in patients with distant
metastases; none had thyroid remnant ablation with radi-
oactive iodine [4]. They reported an overall survival rate of
90.5% and noted that age, size of tumour and extent of
resection adversely affected the prognosis.
Hürthle cell lesion can be easily picked up on FNAC but
to make a diagnosis of HCC one has to demonstrate vas-
cular or capsular invasion. Intraoperative frozen sections
have low predictive value and cases with advanced age
(over 50), rapid enlargement of lump and palpable nodes
should be regarded with high index of suspicion for pres-
ence of HCC. HCC or other differentiated carcinomas of
thyroid in the elderly patients are generally more aggres-
sive with less favourable prognosis compared to younger
patients. They should be offered total thyroidectomy and
selective lymph node dissection (when lymph nodes are
involved) followed by ablative radioiodine therapy, pro-
vided they can withstand the above treatment. Coexisting
medical disorders should be recognized and managed
effectively prior to surgery [31]. Further research is needed
to clarify the role of adjuvant radioiodine therapy in the
management of HCC.
photomicrograph showing Hürthle cell note the eosinophilic cytoplasm and prominent nucleoli (Haematoxylin and Eosin ×500) Figure 4
photomicrograph showing Hürthle cell note the eosinophilic cytoplasm and prominent nucleoli (Haematoxylin and Eosin 
×500).World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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Whole body scan on November 3, 2003 following 131I ablation therapy on 28th October 2003, with 3060 MBq Sodium Iodine  (131I) Figure 5
Whole body scan on November 3, 2003 following 131I ablation therapy on 28th October 2003, with 3060 MBq Sodium Iodine 
(131I). Increased uptake is seen in the region of the thyroid bed. No abnormal accumulation was noted elsewhere.World Journal of Surgical Oncology 2004, 2:27 http://www.wjso.com/content/2/1/27
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Whole body scan on 19th April 2004 following 131I ablation therapy on 13th April 2004 with 5911 MBq Sodium Iodine (131I) Figure 6
Whole body scan on 19th April 2004 following 131I ablation therapy on 13th April 2004 with 5911 MBq Sodium Iodine (131I). 
Two small focal area of uptake are seen in the thyroid bed. Low uptake focal area in the left lateral aspect of the neck, could 
possibly represent activity in a cervical node.Publish with BioMed Central    and   every 
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